Physician profile
Raiqa Munis
NPI 1245240563
$2,371.64
in general payments reported to CMS, 2019-2025
14 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $320 · 2021: $440 · 2022: $313 · 2023: $310 · 2024: $326 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $679.42 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $376.07 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $310.47 | 2019-2023 | Xarelto |
| Amgen INC. | $256.36 | 2023-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.09 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $182.39 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $134.09 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $40.72 | 2019-2025 | Veozah |
| Pfizer INC. | $39.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $34.15 | 2019 | |
| Merck Sharp & Dohme LLC | $25.54 | 2019 | |
| Exact Sciences Corporation | $18.15 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $15.90 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $15.25 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raiqa Munis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.